DC 2: Alisa Kirkin
Alisa Kirkin (Germany) recently graduated from the International Master in Innovative Medicine (IMIM) program, where she received interdisciplinary training in molecular biology, immunology, and translational medicine, and gained research experience in both academic and industrial settings.
She completed her master’s thesis at AstraZeneca in Gothenburg, where she developed high-throughput NanoBRET and Nano-Glo assays to study PROTAC-mediated protein degradation. Prior to this, she worked at Molecular Partners in Zurich, applying multicolor flow cytometry to profile immune cell dynamics in preclinical tumor models.
Alisa has also contributed to projects on gene silencing and blood-brain barrier transporter studies during her bachelor’s thesis at the University of Heidelberg, and has undertaken internships on cardiomyocyte metabolism, cancer cell drug responses, and immunoassay development.
In parallel with her studies, she works as a freelance science writer for Inside Precision Medicine, reporting on emerging developments in molecular biology and biotechnology.
Since September 2025, she has been pursuing a PhD in Prof. Claudio De Virgilio’s group at the University of Fribourg, investigating non-canonical mTOR signaling in yeast.
Planned secondments: 3 months at Fondazione Telethon (TIGEM) for validation of new yeast regulators of NC-TORC1 in mammalian systems. 3 months at BioSolveIT for drug modelling of RAGs.

Fondazione Teletogn (TIGEM)
3 monthsPozzuoli, Italy

BioSolveIT
3 monthsSankt Augustin, Germany
My research project
My project will address the still elusive mechanism of how the Rag GTPases control TORC1 in yeast. Unlike in mammalian cells where the Rag GTPases serve to tether mTORC1 to lysosomes, yeast Rag GTPases control vacuolar TORC1 primarily via an elusive mechanism that neither involves membrane recruitment nor the regulation via the Rheb-orthologous Rhb1 (own unpublished data). An appealing explanation for this mystery relates to the recently discovered non-canonical Rag GTPase-mTORC1 (NC-mTORC1) pathway.
We speculate that also the RagC/D orthologue Gtr2 in yeast locally couples TORC1 to specific substrates. To address this, the doctoral candidate will probe both the interactome and proxisome by MS-coupled Turbo-BioID of wild-type and GDP- or GTP-locked alleles of Rag GTPases. Our preliminary data with Gtr2 identify all known TORC1 effectors, and hitherto unknown candidates. Doctoral candidate will validate them by co-IP and in vitro TORC1 kinase assays followed by MS-based identification of the TORC1 target residues. Using a combination of two-hybrid, co-IP, and Alpha-Fold-assisted modeling, DC2 will map the interaction surfaces on both the Rag GTPase and the novel effectors to denominate a common Rag GTPase interaction motif in the effector proteins. Emerging models will be tested by CRISPR/Cas9-mediated introduction of point mutations in the interaction domains that should affect binding and the biological function of the respective TORC1 effectors.